Synthetic Biology Innovations Need a Clear Path to Market

October 30, 2015

(Washington Post) – A new report from the Wilson Center’s Synthetic Biology Project highlights the need to modernize the complex and often times contradictory regulatory oversight of the synthetic biology industry. Right now, there’s a confusing mix of federal regulators (FDA, USDA and EPA) and an alphabet soup of federal statutes (TSCA, FIFRA, FFDCA, PPA) that result in some synthetic biology products being caught in an innovation no-man’s land. And that could impede some promising innovations from reaching the marketplace, especially those from smaller start-ups